PTIX - Protagenic Therapeutics, Inc.\new

0.3183
-0.069   -21.772%

Share volume: 939,176
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$0.39
-0.07
-0.18%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
16%
Profitability 0%
Dept financing 32%
Liquidity 50%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-23.85%
1 Month
14.46%
3 Months
-41.94%
6 Months
-44.64%
1 Year
-79.20%
2 Year
-81.49%
Key data
Stock price
$0.32
P/E Ratio 
0.00
DAY RANGE
$0.29 - $0.34
EPS 
-$1.46
52 WEEK RANGE
$0.18 - $1.85
52 WEEK CHANGE
-$79.66
MARKET CAP 
2.803 M
YIELD 
N/A
SHARES OUTSTANDING 
4.467 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
-0.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$34,276,898
AVERAGE 30 VOLUME 
$9,937,642
Company detail
CEO: Garo H. Armen
Region: US
Website: protagenic.com
Employees: 2
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Protagenic Therapeutics, Inc. engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide.

Recent news
loading